By Editor • September 3, 2026 • 1 min read
Abivax, a promising French biotech firm, remains unacquired despite expectations of a $20 billion deal, leaving investors concerned.
Read moreBy Editor • September 2, 2026 • 1 min read
Ultragenyx's GTX-102 for Angelman syndrome has failed a Phase 3 trial, dashing hopes for affected families and the company's profitability.
Read moreBy Editor • September 2, 2026 • 1 min read
ARPA-H is funding biotechs developing personalized RNA therapies, while UniQure seeks approval for its Huntington's disease treatment.
Read moreBy Editor • August 31, 2026 • 1 min read
Researchers are exploring how pregnancy hormones might innovate cardiovascular treatment strategies.
Read moreBy Editor • August 29, 2026 • 2 min read
Vijay Pande has shifted from managing a $4 billion fund at a16z to a new venture focused on concentrated biotech investments and leveraging AI in medicine.
Read moreBy Editor • August 28, 2026 • 1 min read
Cytokinetics reveals positive data for aficamten, targeting nHCM, and plans FDA submission by year-end for potential approval.
Read moreBy Editor • August 27, 2026 • 1 min read
Merck and Moderna's personalized cancer vaccine may be the first to use an algorithm for its genetic design, but skepticism remains about its necessity.
Read moreBy Editor • August 24, 2026 • 1 min read
Lady Gaga and her fiancé have launched a biotech startup, merging their passions for entertainment and innovation in the science sector.
Read moreBy Editor • August 20, 2026 • 1 min read
The FDA has approved Ultragenyx's new gene therapy, marking a notable achievement in the biotech sector.
Read moreBy Editor • August 19, 2026 • 2 min read
Vivodyne's HIVE labs aim to revolutionize drug discovery by addressing AI's data shortcomings in cancer research.
Read more
